Abstract
In postmenopausal women with hormone receptor (HR)-positive breast cancer, neoadjuvant endocrine therapy (ET) provides effective downstaging of tumor for improved surgical outcome and offers an important advantage of assessing tumor endocrine responsiveness for individualized therapy in the adjuvant setting. Although approximately 60 % of breast cancers in premenopausal women are HR positive, the role of neoadjuvant ET in this population is not well defined. We identified 162 patients with stage I-III estrogen receptor-positive breast cancer treated with neoadjuvant ET between 2003 and 2012. Of this group, 17 patients were premenopausal. Data included patient/tumor characteristics, surgical, systemic, and radiation treatment received, and outcomes. Descriptive statistics were used for data summary. The cohort included 17 patients with a mean age of 46.2 years (range 39-53 years). Patients were treated with a combination of gonadotrophic-releasing hormone agonist with either an aromatase inhibitor (n = 14) or tamoxifen (n = 3) for 4-6 months. Among the premenopausal patients, six underwent breast-conserving therapy, with 3 of 6 (50.0 %) having positive margins. Adjuvant chemotherapy was recommended for 13 (76.5 %), and adjuvant ...Continue Reading
References
Jan 1, 1992·Breast Cancer Research and Treatment·J RussoI H Russo
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M HarveyD C Allred
May 20, 2000·Journal of Mammary Gland Biology and Neoplasia·I H Russo, J Russo
Feb 2, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W EiermannUNKNOWN Letrozole Neo-Adjuvant Breast Cancer Study Group
Oct 16, 2002·Annals of Internal Medicine·Sharon H GiordanoGabriel N Hortobagyi
Jun 16, 2004·Cancer·Gordon F Schwartz, Gabriel N Hortobagyi
Jun 29, 2004·Cancer·Sharon H GiordanoGabriel N Hortobagyi
Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marco ColleoniAron Goldhirsch
May 17, 2005·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Jul 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian E SmithUNKNOWN IMPACT Trialists Group
Apr 7, 2006·Cancer·Luigi CataliottiCelia Tosello de Oliveira
Apr 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannGunter von Minckwitz
Mar 8, 2007·Cancer·Zeina A NahlehRami Komrokji
Jun 1, 2007·Cancer·Vladimir F SemiglazovLev M Berstein
Aug 23, 2007·British Journal of Cancer·R TorrisiM Colleoni
Nov 21, 2007·Breast Cancer Research and Treatment·Matthew J Ellis, Cynthia Ma
Feb 9, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R GralowEric P Winer
Dec 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettRichard Peto
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew J EllisJohn A Olson
Aug 2, 2011·Lancet·C DaviesR Peto
Jun 8, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E AlbaUNKNOWN GEICAM
Sep 14, 2012·Cancer·Hiroji IwataShinzaburo Noguchi
Jan 24, 2013·Cancer·Mariana Chavez-MacgregorSharon H Giordano
Jul 31, 2013·Cancer Treatment Reviews·A CharehbiliC J H van de Velde
Jan 15, 2014·Breast Care·Hans-Joerg Senn
Dec 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E AlbaUNKNOWN GEICAM
Citations
Jan 19, 2016·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·P A van DamX B Trinh
Nov 8, 2016·Bulletin du cancer·Paul H Cottu
May 29, 2020·Breast Cancer Research : BCR·Hee Jeong KimSei Hyun Ahn
Jul 26, 2019·Annals of Surgical Oncology·M J ThorntonO M Fayanju
Oct 19, 2021·Frontiers in Oncology·Sungchan GwarkHee Jeong Kim